# \[E\]PANOVA Combined With a \[S\]TATIN in \[P\]ATIENTS With HYPERT\[R\]IGLYCER\[I\]DEMIA to Reduce Non-HDL CHOLES\[T\]EROL

Study · id `cardio:ct-nct01408303` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01408303](<https://clinicaltrials.gov/study/NCT01408303>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01408303

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 646 participants.

## Technical summary

Registry record NCT01408303. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-06 (actual). Results posted on 2014-12-05.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 646 participants (enrolled count; ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Start date: 2011-08 (registry gives no type) (ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Primary completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Completion: 2012-06 (actual) (ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Results first posted: 2014-12-05 (ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01408303, source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01408303-2014-12-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: \[E\]PANOVA Combined With a \[S\]TATIN in \[P\]ATIENTS With HYPERT\[R\]IGLYCER\[I\]DEMIA to Reduce Non-HDL CHOLES\[T\]EROL
- Acronym: ESPRIT
- Condition: Hypertriglyceridemia
- Condition: Cardiovascular Disease
- Intervention (Drug): Olive oil, 4g
- Intervention (Drug): omega-3-carboxylic acids, 2g
- Intervention (Drug): omega-3-carboxylic acids, 4g
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Omthera Pharmaceuticals, Inc
- Collaborator class: INDUSTRY
- Collaborator: Medpace, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High triglycerides (`cardio:hypertriglyceridemia`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Medpace, Inc. (`cardio:org-medpace-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial) (`cardio:pubmed-23998969`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial (`cardio:pubmed-26328624`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 701c305afb61578f57d4170f026f9901a0f51a6694e80fa463d8b7ef41c9258d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
